<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 14 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:inherit;
panose-1:0 0 0 0 0 0 0 0 0 0;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
h1
{mso-style-priority:9;
mso-style-link:"Heading 1 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:24.0pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
h3
{mso-style-priority:9;
mso-style-link:"Heading 3 Char";
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:13.5pt;
font-family:"Times New Roman","serif";
font-weight:bold;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0in;
mso-margin-bottom-alt:auto;
margin-left:0in;
font-size:12.0pt;
font-family:"Times New Roman","serif";}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri","sans-serif";
color:windowtext;}
span.Heading1Char
{mso-style-name:"Heading 1 Char";
mso-style-priority:9;
mso-style-link:"Heading 1";
font-family:"Times New Roman","serif";
font-weight:bold;}
span.Heading3Char
{mso-style-name:"Heading 3 Char";
mso-style-priority:9;
mso-style-link:"Heading 3";
font-family:"Times New Roman","serif";
font-weight:bold;}
span.by-author
{mso-style-name:by-author;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
span.author
{mso-style-name:author;}
span.posted-on
{mso-style-name:posted-on;}
span.sharing-screen-reader-text
{mso-style-name:sharing-screen-reader-text;}
span.share-count
{mso-style-name:share-count;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri","sans-serif";}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:1440373161;
mso-list-template-ids:-887169524;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:1.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:1.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:2.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:3.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.0in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:4.5in;
mso-level-number-position:left;
text-indent:-.25in;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0in;}
ul
{margin-bottom:0in;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-US link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><a href="http://stateofreform.com/news/industry/healthcare-providers/2015/06/ca-senate-committee-to-hear-right-to-try-bill/?cal">http://stateofreform.com/news/industry/healthcare-providers/2015/06/ca-senate-committee-to-hear-right-to-try-bill/?cal</a><o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><h1 style='vertical-align:baseline'><span style='font-family:"inherit","serif";color:#222222'>CA: Senate committee to hear “Right to Try” bill<o:p></o:p></span></h1><p class=MsoNormal><span class=by-author><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'>By</span></span><span class=apple-converted-space><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'> </span></span><span class=author><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'><a href="http://stateofreform.com/author/jon/" title="View all posts by Jon Brumbach"><span style='color:#999999'>Jon Brumbach</span></a></span></span><span class=apple-converted-space><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'> </span></span><span class=posted-on><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'>,</span></span><span class=apple-converted-space><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'> </span></span><span class=author><span style='font-size:9.5pt;border:none windowtext 1.0pt;padding:0in'><a href="http://stateofreform.com/news/industry/healthcare-providers/2015/06/ca-senate-committee-to-hear-right-to-try-bill/" title="8:00 am"><span style='color:#999999'>June 12, 201</span><span style='color:#999999'>5</span></a></span></span><span style='font-family:"Times New Roman","serif"'><o:p></o:p></span></p><p style='margin:0in;margin-bottom:.0001pt;background:white;vertical-align:baseline'><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'><o:p> </o:p></span></p><p style='margin:0in;margin-bottom:.0001pt;background:white;vertical-align:baseline'><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'>SACRAMENTO — The Senate Health committee will consider legislation that would streamline access to experimental treatments for terminally ill patients.</span><span class=apple-converted-space><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'> </span></span><span style='font-size:9.5pt;font-family:"Helvetica","sans-serif";color:#373940'><a href="http://leginfo.legislature.ca.gov/faces/billHistoryClient.xhtml" target="_blank"><span style='font-size:12.0pt;color:#0073AD;border:none windowtext 1.0pt;padding:0in'>AB 159</span></a>, also known as the “Right to Try Act”, would allow manufacturers to provide, and physicians to prescribe, a drug, biological product, or device not yet approved by the Food and Drug Administration (FDA) when the patient has a serious or immediate life-threatening condition. Insurance carriers would have the option to cover such treatments, but are not required to do so…<o:p></o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>Cool! When I had a terminal family member I started a thread on this. If we already know what will happen if they stay the course, and we have a willing patient, why not try some wacky theoretical medication or therapy? Document carefully what was taken and what happened. We create an online database of some sort, then let a million amateur dataminers try to find a pattern. That way we shuffle off this mortal coil at least contributing something to humanity, even if it is just one more negative data point.<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>It is easy to imagine a guy with only months to live (and good indications those months will suck) saying to his bride: We should try something, anything. Hell Mary, we know what happens if we do nothing…<o:p></o:p></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal>spike<o:p></o:p></p></div></body></html>